Adoptive-cell-transfer therapy for the treatment of patients with cancer

被引:524
作者
Dudley, ME [1 ]
Rosenberg, SA [1 ]
机构
[1] NCI, Surg Branch, Bethesda, MD 20892 USA
关键词
D O I
10.1038/nrc1167
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adoptive immunotherapy - the isolation of antigen-specific cells, their ex vivo expansion and activation, and subsequent autologous administration - is a promising approach to inducing antitumour immune responses. The molecular identification of tumour antigens and the ability to monitor the persistence and transport of transferred cells has provided new insights into the mechanisms of tumour immunotherapy. Recent studies have shown the effectiveness of cell-transfer therapies for the treatment of patients with selected metastatic cancers. These studies provide a blueprint for the wider application of adoptive-cell-transfer therapy, and emphasize the requirement for in vivo persistence of the cells for therapeutic efficacy.
引用
收藏
页码:666 / U2
页数:11
相关论文
共 102 条
[61]   gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand [J].
Overwijk, WW ;
Tsung, A ;
Irvine, KR ;
Parkhurst, MR ;
Goletz, TJ ;
Tsung, K ;
Carroll, MW ;
Liu, CL ;
Moss, B ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (02) :277-286
[62]  
OVERWIJK WW, IN PRESS J EXP MED
[63]   Treatment of subcutaneous tumor with adoptively transferred T cells [J].
Peng, LM ;
Shu, SY ;
Krauss, JC .
CELLULAR IMMUNOLOGY, 1997, 178 (01) :24-32
[64]   Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma [J].
Phan, GQ ;
Yang, JC ;
Sherry, RM ;
Hwu, P ;
Topalian, SL ;
Schwartzentruber, DJ ;
Restifo, NP ;
Haworth, LR ;
Seipp, CA ;
Freezer, LJ ;
Morton, KE ;
Mavroukakis, SA ;
Duray, PH ;
Steinberg, SM ;
Allison, JP ;
Davis, TA ;
Rosenberg, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) :8372-8377
[65]   Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma [J].
Phan, GQ ;
Attia, P ;
Steinberg, SM ;
White, DE ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) :3477-3482
[66]   T-cell adoptive immunotherapy of metastatic renal cell carcinoma [J].
Plautz, GE ;
Bukowski, RM ;
Novick, AC ;
Klein, EA ;
Kursh, ED ;
Olencki, TE ;
Yetman, RJ ;
Pienkny, A ;
Sandstrom, K ;
Shu, SY .
UROLOGY, 1999, 54 (04) :617-623
[67]  
Prévost-Blondel A, 1998, J IMMUNOL, V161, P2187
[68]   Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas [J].
Quattrocchi, KB ;
Miller, CH ;
Cush, S ;
Bernard, SA ;
Dull, ST ;
Smith, M ;
Gudeman, S ;
Varia, MA .
JOURNAL OF NEURO-ONCOLOGY, 1999, 45 (02) :141-157
[69]   A listing of human tumor antigens recognized by T cells [J].
Renkvist, N ;
Castelli, C ;
Robbins, PF ;
Parmiani, G .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (01) :3-15
[70]   A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes [J].
Robbins, PF ;
ElGamil, M ;
Li, YF ;
Kawakami, Y ;
Loftus, D ;
Appella, E ;
Rosenberg, SA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :1185-1192